文献速递神经肿瘤

原发性脑肿瘤患者接种BNT162b2 mRNA COVID-19疫苗的免疫原性:一项前瞻性队列研究

Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study.
PubMed 文献 · J Neurooncol · 2022-01-12

该前瞻性队列研究评估了17例原发性脑肿瘤(PBT)患者接种两剂BNT162b2疫苗后的IgG抗体水平,并与健康对照(HC)比较。结果显示多数PBT患者成功血清转化,但抗体滴度显著低于HC;接种期间使用类固醇与较低抗体滴度相关。

要点

  • PBT患者接种两剂BNT162b2后多数可血清转化,但抗体滴度低于健康对照。
  • 接种期间使用类固醇与较低抗体滴度相关。
  • T2时3例未血清转化者均接受类固醇治疗。

核心结论

  • 多数PBT患者接种两剂BNT162b2疫苗后成功血清转化,但抗体滴度低于健康对照。
  • 接种期间使用类固醇与较低抗体滴度相关。

研究设计与样本

  • 前瞻性队列研究,纳入17例原发性脑肿瘤患者,接种两剂BNT162b2疫苗。
  • 在第二剂后中位44天(T1)和中位130天(T2)检测抗SARS-CoV-2刺突蛋白IgG水平。
  • 对照为患者家属组成的健康对照组。

主要发现

  • T1时PBT组血清转化率88.2%(15/17),健康对照组100%(12/12)。
  • T1时PBT组中位IgG滴度1908 AU/mL,健康对照组8198 AU/mL,p=0.002。
  • T2时PBT组血清转化率80%(12/15),健康对照组100%(10/10)。
  • T2时PBT组中位IgG滴度410 AU/mL,健康对照组1687 AU/mL,p=0.002。
  • 接种期间15例接受全身治疗,8例接受皮质类固醇治疗;T2时3例未血清转化者均接受皮质类固醇治疗;单变量分析中类固醇使用与抗体滴度负相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immunogenicity of Covid-19 vaccines may be negatively impacted by anti-cancer treatment. The management of primary brain tumors (PBTs) routinely includes temozolomide and steroids, which are immune-suppressive. We aimed to determine the rate of seropositivity in PBT patients following receipt of two doses of the BNT162b2 vaccine. METHODS: We prospectively evaluated IgG levels against SARS-CoV-2 spike protein in 17 PBT patients following two doses of the BNT162b2 vaccine. IgG levels were collected at two time points: T1-after a median of 44 days from the second vaccine dose and T2-after a median of 130 days from the second dose. Titers were compared against a group of healthy controls (HC) comprised of patients' family members. RESULTS: At T1, 88.2% (15/17) of PBT patients achieved seroconversion, compared with 100% (12/12) of HCs. Median IgG titer was significantly lower in the PBT group (1908 AU/mL vs 8,198 AU/mL; p = 0.002). At T2, 80% (12/15) of PBT patients seroconverted, compared to 100% (10/10) of HCs. Median IgG titer remained significantly lower in the PBT group (410 AU/mLvs 1687 AU/mL; p = 0.002). During the peri-vaccination period, 15 patients received systemic treatment and 8 patients were treated with corticosteroids. All 3 patients who failed to seroconvert at T2 were treated with corticosteroids. In a univariate analysis, steroid use was negatively associated with antibody titer. CONCLUSION: Most PBT patients successfully seroconvert following two doses of the BNT162b2 vaccine, albeit with lower antibody titer compared to HCs. Steroid use during the vaccination period is associated with lower titer.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Massarweh A, Tschernichovsky R, Stemmer A, et al. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study. J Neurooncol. 2022. PMID: 35018613. doi:10.1007/s11060-021-03911-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。